Tablet: Each enteric-coated tablet contains Rabeprazole Sodium INN 20 mg.
Rabifast® is enteric coated tablet which is a preparation of Rabeprazole Sodium INN. It is an antiulcer drug in the class of proton pump inhibitors (PPIs). Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H+/ K+ ATPase at the secretory surface of the gastric parietal cell. This enzyme is regarded as the acid (proton) pump within the parietal cell. Rabeprazole blocks the final step of gastric acid secretion. The stability of Rabeprazole Sodium depends on pH. It is rapidly degraded in acid media and is more stable under alkaline conditions. Because of its enteric coated formulation Rabifast is highly stable in stomach and higher pKa value of Rabeprazole provides faster action compared to other PPls.
Rabifast® tablet should be swallowed whole. The tablet should not be chewed, crushed or split.
Pregnant women: FDA approved pregnancy category B. Lactating mother: It is not known if unmetabolized Rabeprazole is excreted in human breast milk.
PEDIATRIC USE Use of Rabeprazole in adolescent patients 12 years of age and above for short-term treatment of GERD is supported. But the safety and effectiveness of Rabeprazole for the treatment of GERD patients <12 years of age have not been established. The safety and effectiveness of Rabeprazole for other uses have not been established in pediatric patients.
e Symptomatic response to therapy with Rabeprazole does not preclude the presence of gastric malignancy Patients treated with a proton pump inhibitor and warfarin may need to be monitored for increases in INR and prothrombin time due to risk of abnormal bleeding Bone Fracture: Long-term and multiple daily dose PPI therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine Hypomagnesemia has been reported rarely with prolonged treatment with PPls.
Do not store above 25°C temperature. Keep away from light and wet place. Keep out of reach of children.